193 related articles for article (PubMed ID: 8149890)
1. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
de Miranda P; Burnette TC
Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
Burnette TC; de Miranda P
Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
[TBL] [Abstract][Full Text] [Related]
3. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
[TBL] [Abstract][Full Text] [Related]
10. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.
Spruance SL; Tyring SK; DeGregorio B; Miller C; Beutner K
Arch Intern Med; 1996 Aug 12-26; 156(15):1729-35. PubMed ID: 8694673
[TBL] [Abstract][Full Text] [Related]
11. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
[TBL] [Abstract][Full Text] [Related]
13. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
Jacobson MA
J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
15. Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.
Good SS; Krasny HC; Elion GB; de Miranda P
J Pharmacol Exp Ther; 1983 Dec; 227(3):644-51. PubMed ID: 6655561
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Choi WS; Im GJ; Kim DK; Kim TK; Jung I; Kim TS; Lee SJ; Lee N; Kim YW; Kim JS; Chang K
Drug Metab Dispos; 2001 Jul; 29(7):945-9. PubMed ID: 11408358
[TBL] [Abstract][Full Text] [Related]
18. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
19. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
20. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
